Adicet Bio announced the completion of the last patient visit for the planned Phase 1 safety and efficacy analysis of prula-cel in patients with systemic lupus erythematosus (SLE) with or without lupus nephritis. Topline data from this analysis, which includes 22 SLE patients, is expected to be reported in September 2026. The company also disclosed FDA clearance of its Investigational New Drug application for ADI-212, a gene-edited cell therapy candidate for metastatic castration-resistant prostate cancer (mCRPC), with Phase 1 enrollment planned for the fourth quarter of 2026. Additionally, Adicet is advancing its in vivo CAR-T platform, expecting the first candidate to enter clinical development in the second half of 2027. Adicet Bio operates as a clinical-stage biotechnology company developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases and cancers.

Adicet Bio reported a net loss of $21.4 million for the quarter ended June 30, 2026, or $1.99 per share, with cash and short-term investments totaling $118.2 million. The company announced that Lloyd Klickstein has been appointed Interim Chief Medical Officer following the departure of Dr. Julie Maltzman. Clinically, Adicet plans to provide a comprehensive Phase 1 update for prulacabtagene leucel in lupus nephritis and systemic lupus erythematosus in Q3 2026, featuring data from 22 patients with at least six months of follow-up. The company also anticipates initiating startup activities for a potential pivotal trial in the second half of 2026 following productive FDA interactions. Additionally, Adicet expects to submit a regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer in Q3 2026, with Phase 1 enrollment anticipated in Q4 2026. Adicet Bio is a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.